Your trusted source for clear, analytical news.

Company

About Us Contact Us Authors Feedback Grievance

Legal

Sun Pharma Q2 EBITDA Margin 29.3%, Surpasses Estimates, Shares Rise 3.5% | AirNews.in

stocks

SJVN Net Profit Soars to ₹657.4 Cr, EBITDA Up 84.3% in Q2 Vinati Organics Q2 Net Profit Slides 28% To ₹78.4 Crore Despite ₹500 Crore Capex Plan Sensex Climbs 0.42% to 74,459.5, IT Stocks Drive Rally Navin Fluorine Q2 Profit Soars 81.8%, Shares Rise 5.5%eMudhra Shares Plunge 20% After Key Generation Breach Gujarat Mineral Development Corp Q2 Revenue Soars 71.2%, Net Profit Falls 63%GAIL Q2 Revenue Surges 17.8% to ₹45,895 Cr, Beats Street Estimates Gold Futures Slide 0.58% as Spot Falls Below $4,000 Mark Intellect Design Arena Q2 Net Profit Hits ₹104 Cr, Shares Drop 8.5%Network18 Media Q2 Revenue Jumps 9.4% to ₹545 Cr, EBITDA Turns Positive SJVN Net Profit Soars to ₹657.4 Cr, EBITDA Up 84.3% in Q2 Vinati Organics Q2 Net Profit Slides 28% To ₹78.4 Crore Despite ₹500 Crore Capex Plan Sensex Climbs 0.42% to 74,459.5, IT Stocks Drive Rally Navin Fluorine Q2 Profit Soars 81.8%, Shares Rise 5.5%eMudhra Shares Plunge 20% After Key Generation Breach Gujarat Mineral Development Corp Q2 Revenue Soars 71.2%, Net Profit Falls 63%GAIL Q2 Revenue Surges 17.8% to ₹45,895 Cr, Beats Street Estimates Gold Futures Slide 0.58% as Spot Falls Below $4,000 Mark Intellect Design Arena Q2 Net Profit Hits ₹104 Cr, Shares Drop 8.5%Network18 Media Q2 Revenue Jumps 9.4% to ₹545 Cr, EBITDA Turns Positive

PharmaSun PharmaQ2 ResultsEBITDAStock Market

Sun Pharma Q2 EBITDA Margin 29.3%, Surpasses Estimates, Shares Rise 3.5%

about 2 hours ago

Published: October 30, 2026

Sun Pharma Q2 EBITDA Margin 29.3%, Surpasses Estimates, Shares Rise 3.5%

Sun Pharma reported Q2 revenue of ₹16,198.7 crore, up 12% YoY and beating the ₹15,766.1 crore consensus. Shares rallied 3.5% to ₹1,820, while analysts note margin expansion to 29.3% amid rising acquisition costs.

Shares lifted 3.5% to ₹1,820 after Sun Pharma disclosed Q2 revenue of ₹16,198.7 crore, eclipsing the ₹15,766.1 crore consensus on the BSE/NSE.

EBITDA rose to ₹4,743 crore, up from ₹4,527 crore last year, pushing margin to 29.3% versus 31.3% y/y and 27.9% market, per the filing.

Net profit hit ₹1,988.5 crore, a 36% drop from the ₹3,085 crore consensus and 36% lower than the same quarter last year, largely due to a ₹1,270 crore exceptional loss on legal and acquisition fees, as disclosed by the management.

US sales dipped 8.2% YoY to $455 million, 27% of consolidated revenue; innovative medicines held steady, while emerging markets grew 7.6% to $350 million, according to the quarter report.

Management warns that acquisition‑related costs will recur, but robust API sales of ₹488.9 crore and margin expansion suggest resilience. Investors await Q3 guidance slated for May, with analysts monitoring the impact of the Organon deal.